Lupin has announced that it has partnered with Mylan to commercialize Enbrel (Etanercept) biosimilar. Under the terms of the agreement, Lupin will receive an up-front payment of $15mn and potential commercial milestones together with an equal share in net profits of the product. Mylan will commercialize Lupin's Etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.